Street Calls of the Week
LONDON - EKF Diagnostics Holdings plc (AIM:EKF) has implemented a new Long Term Incentive Plan (LTIP) for its senior executives, the company announced Tuesday in a press release.
The AIM-listed diagnostics business has awarded Chief Executive Officer Gavin Jones options over 500,000 ordinary shares under the plan, which was adopted on September 9, 2025.
The performance-based award has a three-year measurement period from the grant date and includes specific vesting criteria tied to the company’s financial results. According to the terms, 100% of the award will vest if Adjusted EBITDA per share grows by 25% or more over the performance period. For growth between 10% and 25%, vesting will occur on a sliding scale from 25% to 100%, while growth below 10% will result in no vesting.
Jenny Winter, Chair of the Remuneration Committee, stated in the release: "It is important that Gavin is rewarded in a way which links his performance with shareholder value creation. I am satisfied that these incentivisation arrangements achieve that objective."
The company noted that the LTIP was established after consulting with certain shareholders and receiving recommendations from its remuneration committee and advisers.
EKF Diagnostics specializes in point-of-care analyzers for hematology and diabetes, as well as life sciences services providing enzymes and custom products for diagnostic, food, and industrial applications. The company operates five manufacturing facilities across the US and Germany and sells into more than 120 countries worldwide.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.